Therefore, the clinicians should pay more attention to the long-term follow-up of ER/PR+, HER2−, and PR ≥ 20% subtype breast cancer patients aged ≥ 41years (equivalent to the peri- and postmenopausal period in China) more than 3 years after surgery. This evidence concerns the gene PGR and breast carcinoma.